Mount Yale Investment Advisors LLC Has $1.09 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Mount Yale Investment Advisors LLC raised its position in shares of Cencora, Inc. (NYSE:COR) by 5.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,836 shares of the company’s stock after purchasing an additional 266 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Cencora were worth $1,090,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. acquired a new position in shares of Cencora during the 4th quarter worth $4,212,508,000. Price T Rowe Associates Inc. MD bought a new position in Cencora in the first quarter valued at about $2,183,619,000. JPMorgan Chase & Co. acquired a new position in Cencora during the first quarter worth about $1,199,695,000. Boston Partners acquired a new stake in shares of Cencora in the 1st quarter valued at approximately $1,001,269,000. Finally, Capital Research Global Investors bought a new stake in shares of Cencora during the 1st quarter valued at approximately $650,424,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Stock Up 0.7 %

Shares of NYSE COR opened at $228.11 on Monday. The company’s 50 day moving average price is $234.84 and its 200-day moving average price is $233.10. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. Cencora, Inc. has a 52-week low of $178.21 and a 52-week high of $247.66. The company has a market capitalization of $45.50 billion, a P/E ratio of 24.96, a price-to-earnings-growth ratio of 1.55 and a beta of 0.44.

Cencora (NYSE:COR) last released its earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The business had revenue of $74.20 billion for the quarter, compared to analyst estimates of $73.32 billion. During the same quarter in the previous year, the business earned $2.92 earnings per share. Cencora’s revenue for the quarter was up 10.8% on a year-over-year basis. Equities analysts forecast that Cencora, Inc. will post 13.63 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were paid a dividend of $0.51 per share. The ex-dividend date was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.89%. Cencora’s dividend payout ratio is currently 22.32%.

Insiders Place Their Bets

In other Cencora news, CEO Steven H. Collis sold 10,755 shares of the stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $222.12, for a total transaction of $2,388,900.60. Following the transaction, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of the company’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $240.56, for a total transaction of $1,067,646,415.76. Following the transaction, the insider now owns 19,980,000 shares in the company, valued at $4,806,388,800. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven H. Collis sold 10,755 shares of the firm’s stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the completion of the sale, the chief executive officer now owns 285,088 shares of the company’s stock, valued at $63,323,746.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,450,399 shares of company stock worth $1,070,392,799. 15.80% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently weighed in on COR. Leerink Partners reissued an “outperform” rating and set a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. Robert W. Baird cut their price target on Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research note on Friday, September 6th. JPMorgan Chase & Co. upped their price objective on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Bank of America reiterated a “neutral” rating and set a $245.00 target price (down from $275.00) on shares of Cencora in a research report on Wednesday, September 18th. Finally, StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and a consensus target price of $256.67.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.